Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
The robotic surgery program has continually pushed the boundaries of medical technology
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Subscribe To Our Newsletter & Stay Updated